Eli Lilly and Company (LLY) Financials
PeriodQ2 FY2026Q1 FY2026
Published
Eli Lilly and Company reported $22.97 billion in revenue for Q2 FY2026, the quarter ended June 30, 2026, up 47.7% from a year earlier, led by its incretin medicines, with Mounjaro at $9.94 billion and Zepbound at $4.93 billion. Net income was $7.09 billion, up 25.3%, and diluted earnings per share were $7.94. Earnings grew more slowly than revenue because acquired in-process research and development charges from the period's asset acquisitions rose to $2.78 billion from $154 million a year earlier, and Eli Lilly also recorded asset impairment, restructuring and other special charges tied to closed business combinations, having recorded none in the same quarter a year earlier.
| Metric | Amount | vs. year ago |
|---|---|---|
| Revenue | $22,974,000,000 | up 47.7% |
| Net income | $7,095,000,000 | up 25.3% |
| Diluted EPS | $7.94 | up 26.2% |
| Mounjaro revenue | $9,943,000,000 | up 91.2% |
| Zepbound revenue | $4,928,000,000 | up 45.8% |
| Acquired IPR&D | $2,776,000,000 | up 1,702.6% |
Company details
| Name | ELI LILLY & Co |
|---|---|
| Ticker | LLY |
| CIK | 0000059478 |
| Exchange | NYSE |
| State | Indiana |
| Incorporation | Indiana |
| SIC | 2834 |
| Office | Life Sciences |
| Industry | Pharmaceutical Preparations |
| Latest period covered | Q2 FY2026, ended 2026-06-30, 10-Q, accession 0000059478-26-000081 |
| Fiscal year end | 12/31 (MM/DD) |
| Next expected filing | 10-Q around 2026-10-29 (predicted) |
Data files
- Financial statementsPage Annual financial statements plus the latest quarter: income statement, balance sheet, cash flow. Actual dollars, actual shares. Sourcing notes and uncertainties included.
- 10-K and 10-Q summaryPage Qualitative synthesis of the latest 10-K + 10-Q: business, risk factors (quarter-over-quarter changes flagged), MD&A, legal proceedings, subsequent events.
- 8-K filings and eventsPage Digest of material 8-K filings: earnings headlines, management changes, capital-return and financing actions, governance. SEC accession numbers cited throughout.
FAQ · Eli Lilly Q2 FY2026
How much revenue did Eli Lilly report in Q2 FY2026?
Eli Lilly and Company reported $22.97 billion in revenue for Q2 FY2026, the quarter ended June 30, 2026. That is up 47.7% from $15.56 billion in the same quarter a year earlier.
What were Eli Lilly's net income and earnings per share in Q2 FY2026?
Eli Lilly and Company earned $7.09 billion in Q2 FY2026, up 25.3% from $5.66 billion a year earlier, and diluted earnings per share were $7.94 against $6.29.
How much did Mounjaro and Zepbound generate for Eli Lilly in Q2 FY2026?
Mounjaro revenue was $9.94 billion in Q2 FY2026, up 91.2% from a year earlier, and Zepbound revenue was $4.93 billion, up 45.8%. The two tirzepatide medicines are Eli Lilly's largest products by revenue.
Why did Eli Lilly's profit grow more slowly than its revenue in Q2 FY2026?
Eli Lilly and Company's revenue was up 47.7% in Q2 FY2026 while net income was up 25.3%, because acquired in-process research and development charges rose to $2.78 billion from $154 million and the company recorded asset impairment, restructuring and other special charges that it did not carry a year earlier. Those two items also lifted Eli Lilly's effective tax rate for the quarter.
Where can I get Eli Lilly and Company (LLY) financial data in machine-readable form?
Ticker Scout publishes Eli Lilly and Company's financial statements as JSON at https://tickerscout.ai/lly/financials.json, free, with no API key and no signup. The 10-K and 10-Q narrative and the 8-K events digest are published as Markdown at https://tickerscout.ai/lly/narrative.md and https://tickerscout.ai/lly/events.md. Eli Lilly and Company's SEC CIK is 0000059478. Every figure cites the SEC accession number it came from, so it can be checked against sec.gov.
When does Eli Lilly and Company (LLY) next file with the SEC?
Eli Lilly and Company (LLY) is expected to file its next Form 10-Q with the SEC on or around October 29, 2026. That date is a projection rather than a company-announced date: it is derived from Eli Lilly and Company's own filing history with the SEC, by taking the date the company filed the same fiscal period a year earlier and adding 52 weeks. The most recent periodic report on file is the 10-Q for Q2 FY2026, the period ended 2026-06-30, SEC accession 0000059478-26-000081.
Related companies
How this page was built
This page was built from Eli Lilly and Company's own filings with the SEC, read one at a time, and nothing on it is taken from a pre-tagged dataset, a data vendor or another website. The figures are on the company's own fiscal calendar and in actual dollars, as the filings report them. Where the filings do not support a figure, the record says so instead of reporting a zero; this period names seven such gaps.
A single company files thousands of pages with the SEC in a year, and no two companies file them the same way, so the reading and the assembly here are done by AI rather than by rules that break on the differences. Every pass is then audited back against the filings it came from before the page is published, and anything the filings do not support is left out and named rather than filled in. AI can still make mistakes. That is why the accession numbers are printed: the filing is the authority, and this page is a route to it.
Published by Ticker Scout, an independent publisher of company filings data. About Ticker Scout · Disclaimer
Data extracted from SEC filings (accession numbers cited in each file). The undated URLs hold the latest period and are replaced in place each quarter; every period also stays published at its own dated URL, which never changes. Free to cite with attribution: Ticker Scout (tickerscout.ai). Not investment advice, see the Disclaimer.